Dicerna Pharmaceuticals, a Watertown, MA-based developer of RNA-interference drugs, has raised $5 million in a debt and options financing, according to an SEC filing. Doug Fambrough, who resigned from being a general partner at Boston’s Oxford Bioscience Partners last month to become CEO of Dicerna, told Xconomy at the time that he planned to raise a Series B round of funding for the company within the next few months. Dicerna, which launched in 2007, previously raised $21.4 million in a Series A round of venture capital from Abingworth Management, Oxford, and Skyline Ventures. Here’s an in-depth look at Dicerna’s gene-silencing drugs, which might be able to be effective for longer periods than earlier RNAi therapies.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
